SLAMF7 and Miyoshi myopathy: Similar to BCMA, the signaling lymphocytic activation molecule family 7 (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from MM patients and thus is the target of the humanized monoclonal antibody elotuzumab for MM treatment [14, 15].